1.075
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™ - TipRanks
Cardiol Therapeutics reports positive Phase II myocarditis trial results By Investing.com - Investing.com Australia
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions - Investing News Network
Cardiol Therapeutics (NASDAQ: CRDL) posts Phase II ARCHER myocarditis recovery data - Stock Titan
(CRDL) Stock Analysis and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
What is Cardiol Therapeutics Inc (CRDL) Stock Return on Shareholders’ Capital? - Setenews
Total debt per share of Cardiol Therapeutics Inc. Class A – NEO:CRDL - TradingView
Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress - TipRanks
How does Dyne Therapeutics Inc (DYN) change from a tortoise to a hare? - Setenews
(CRDL) Trading Performance and Risk Management (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics CRDL CN - Smartkarma
Wall Street analysts’ outlook for Edgewise Therapeutics Inc (EWTX) - Setenews
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.00 Average PT from Analysts - Defense World
HC Wainwright & Co. Initiates Coverage of Cardiol Therapeutics (CRDL) with Buy Recommendation - MSN
(CRDL) Market Performance Analysis (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Inc (CT9.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics Reports Q3 2025 Financial Results Amidst Cash Decrease - MSN
Cardiol Therapeutics Inc (CT9.DU) stock price, news, quote and history - Yahoo Finance Australia
Cardiol Therapeutics Inc. (CRDL) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is Cardiol Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Macro Moves & Capital Efficiency Focused Ideas - newser.com
What is the fair value of Cardiol Therapeutics Inc. stock now2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
How Cardiol Therapeutics Inc. stock responds to policy changesWeekly Trend Report & Technical Entry and Exit Tips - newser.com
How Cardiol Therapeutics Inc. stock performs during Fed tightening cyclesTrade Analysis Summary & Real-Time Price Movement Reports - newser.com
Will Cardiol Therapeutics Inc. (CT9) stock recover faster than industry2025 Bull vs Bear & Consistent Return Investment Signals - newser.com
Is Cardiol Therapeutics Inc. (CT9) stock undervalued after correctionJuly 2025 Setups & Detailed Earnings Play Alerts - newser.com
Is Cardiol Therapeutics Inc. stock poised for growthQuarterly Growth Report & Verified Trade Idea Suggestions - newser.com
Historical volatility pattern of Cardiol Therapeutics Inc. visualized2025 Market WrapUp & Growth Focused Stock Reports - newser.com
How buyback programs support Cardiol Therapeutics Inc. (CT9) stockProfit Target & Free High Return Stock Watch Alerts - newser.com
Cardiol Therapeutics Inc. stock chart pattern explainedJuly 2025 Levels & Technical Buy Zone Confirmations - newser.com
Is Cardiol Therapeutics Inc. (CT9) stock undervalued at current priceWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
Key metrics from Cardiol Therapeutics Inc.’s quarterly dataWeekly Trend Recap & High Conviction Buy Zone Picks - newser.com
How to build a custom watchlist for Cardiol Therapeutics Inc.Earnings Summary Report & Weekly High Potential Alerts - newser.com
A better buy-in window may exist right now for Cardiol Therapeutics Inc (CRDL) - Setenews
Cardiol Therapeutics Inc. (CRDL.TO) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Technical analysis overview for Cardiol Therapeutics Inc. stockJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Cardiol Therapeutics wins US patent protection for heart-disease drug platform - Indian Pharma Post
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):